Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management

Launched by SHAANXI HOSPITAL OF TRADITIONAL CHINESE MEDICINE · Nov 30, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring new ways to manage Alzheimer's disease and related conditions, such as mild cognitive impairment and subjective cognitive decline. Participants will receive a combination of treatments, including a type of electrical stimulation and music therapy, to help improve their cognitive abilities and daily living skills. The study will last for 24 weeks, during which participants can also use an intelligent device at home to assist with their treatment.

To join the trial, participants need to be between 55 and 75 years old and show signs of memory decline, but not have severe dementia. They should also be in generally good health without serious other medical conditions that could affect the brain. Throughout the study, participants will receive guidance on their treatment plan and health education related to their daily living. This trial aims to find the best ways to support individuals with early stages of cognitive decline, and participants will be an important part of that discovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meeting the diagnostic criteria of SCD, MCI and mild dementia;
• • Memory decline (self-reported or confirmed by both informants);
• • Age 55-75 years;
• • Memory impairment has not reached the diagnostic criteria of moderate and severe dementia;
• • Hachinski ischemia scale score ≤ 4;
• • Exclude any other systemic diseases that can cause brain dysfunction;
• • Hamilton Depression Scale \< 17;
• • The subject or guardian signed the informed consent.
• Exclusion Criteria:
• • There are advanced, serious or unstable other diseases, such as liver, kidney and other serious primary diseases;
• • Severe hearing and visual impairment, can not cooperate with the assessment;
• • with active epilepsy;
• • Previous history of mental illness;
• • Moderate or severe dementia, cerebral infarction or any physical or mental disorder that may lead to brain dysfunction;
• • Having used other drugs that may cause cognitive function changes or heart, brain, kidney and other important organs failure before inclusion;
• • Under 55 years old or above 75 years old;
• • Unable to cooperate with the completion of the corresponding assessment and inspection and quit;
• • Those who are likely to have poor compliance with the test;
• • Participants in other subjects.